Kopran Ltd (KOPRAN) — shareholding pattern, promoter holding, financials and share price
About Kopran Ltd (KOPRAN)
Kopran Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as KOPRAN and on the BSE under scrip code 524280. Its ISIN is INE082A01010.
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
Kopran Limited is an integrated pharmaceutical company engaged in the manufacture and sale of formulations and active pharmaceutical ingredients (APIs) globally, with a focus on quality and technology. They operate two main business verticals through Kopran Limited and Kopran Research Laboratories Ltd.
Kopran has experienced fluctuating financial performance, with revenue from operations in Q3 2025-26 reaching Rs. 19,428 lakhs. However, EBITDA margins have decreased compared to previous years, indicating potential cost pressures or market competition.
Listed peers in Pharmaceuticals: Wanbury Ltd, Bharat Parenterals Ltd, Shree Ganesh Remedies Ltd, Hexagon Nutrition Ltd, Remus Pharmaceuticals Ltd, Sigachi Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹194.15 a share on 10 Jul 2026, Kopran Ltd (KOPRAN) was valued at a price-to-earnings ratio of 36.42x against an industry P/E of 36.41x and a price-to-book of 1.81x on a book value of ₹107.35 per share as of Mar 2025. Solomo computes return on equity of 4.97% and return on capital employed of 6.73% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 36.42x
- Industry P/E
- 36.41x
- P/B
- 1.81x
- EPS (TTM)
- ₹5.33
- Book value / share
- ₹107.35
- ROE
- 4.97%
- ROCE
- 6.73%
- ROA
- 3.05%
- Debt / equity
- 0.29x
- Dividend yield
- 1.55%
- EBITDA margin
- 9.14%
- 52-week range
- ₹107 – ₹218.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Kopran Ltd (KOPRAN) reported revenue of ₹681 crore, net profit of ₹26 crore and earnings per share of ₹5.33. That compares with revenue of ₹630 crore and net profit of ₹39 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹234 crore and net profit ₹19 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 478 | 551 | 615 | 630 | 681 |
| Net profit (₹ cr) | 61 | 27 | 51 | 39 | 26 |
| EPS (₹) | 12.66 | 5.65 | 10.57 | 7.99 | 5.33 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.19% | 8.61% | 9.84% | 2.44% |
| Profit growth | 9.95% | 19.07% | 31.75% | -24.35% |
| Stock price CAGR | 15% | -2% | 4% | 12% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 44.42% of Kopran Ltd (KOPRAN) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.51% and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹937 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: MADHURI MADHUSUDAN KELA 1.72%, LAXMINARAYAN VYAPAAR P LTD 1.56%, ZAKI ABBAS NASSER 1.34%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 44.42% | - | 0.51% | 0% | 55.58% |
| Mar 2026 | 44.42% | - | 0.57% | 0% | 55.58% |
| Dec 2025 | 44.42% | - | 0.36% | 0% | 55.58% |
| Sep 2025 | 44.42% | - | 0.6% | 0% | 55.58% |
| Jun 2025 | 44.42% | - | 0.76% | 0% | 55.58% |
| Mar 2025 | 44.42% | - | 1.12% | 0% | 55.58% |
| Dec 2024 | 44.46% | - | 0.86% | 0% | 55.54% |
| Sep 2024 | 44.49% | - | 1.32% | 0.22% | 55.51% |